4.4 Article

Constitutional mismatch repair deficiency and childhood leukemia/lymphoma - report on a novel biallelic MSH6 mutation

期刊

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
卷 95, 期 5, 页码 841-844

出版社

FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2009.015503

关键词

constitutional mismatch repair deficiency; hereditary cancer; MSH6; childhood T-cell lymphoma; leukemia

资金

  1. Hannover Biomedical Research School, Graduate School of Excellence, PhD Program Molecular Medicine, Hannover Medical School, Hannover, Germany
  2. EU

向作者/读者索取更多资源

Biallelic mutations of mismatch repair genes cause constitutional mismatch repair deficiency associated with an increased risk for childhood leukemia/lymphoma. We report on a case with constitutional mismatch repair deficiency caused by a novel MSH6 mutation leading to a T-cell lymphoma and colonic adenocarcinoma at six and 13 years of age, respectively. A review of the literature on hematologic malignancies in constitutional mismatch repair deficiency showed that in almost half of the 47 known constitutional mismatch repair deficiency families, at least one individual is affected by a hematologic malignancy, predominantly T-cell lymphomas. However, diagnosing constitutional mismatch repair deficiency may be difficult when the first child is affected by leukemia/lymphoma, but identification of the causative germline mutation is of vital importance: (i) to identify relatives at risk and exclude an increased risk in non-mutation carriers; (ii) to prevent hematopoietic stem cell transplantation from sibling donors also carrying a biallelic germline mutation; and (iii) to implement effective surveillance programs for mutation carriers, that may reduce constitutional mismatch repair deficiency-associated mortality.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Oncology

Report of the fifth meeting of the European Consortium 'Care for CMMRD' (C4CMMRD), Leiden, The Netherlands, July 6th 2019

M. Suerink, K. Wimmer, L. Brugieres, C. Colas, R. Gallon, T. Ripperger, P. R. Benusiglio, E. M. A. Bleiker, Z. Ghorbanoghli, Y. Goldberg, J. C. H. Hardwick, M. Kloor, M. le Mentec, M. Muleris, M. Pineda, C. Ruiz-Ponte, H. F. A. Vasen

FAMILIAL CANCER (2021)

Letter Oncology

Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Li-Fraumeni syndrome

Greta Winter, Renate Kirschner-Schwabe, Stefanie Groeneveld-Krentz, Gabriele Escherich, Anja Moericke, Arend von Stackelberg, Martin Stanulla, Simon Bailey, Lisa Richter, Doris Steinemann, Tim Ripperger, Adela Escudero, Roula Farah, Olli Lohi, Karin Wadt, Marjolijn Jongmans, Nienke van Engelen, Cornelia Eckert, Christian Peter Kratz

LEUKEMIA (2021)

Letter Oncology

Functional classification of RUNX1 variants in familial platelet disorder with associated myeloid malignancies

Melanie Decker, Tim Lammens, Alina Ferster, Miriam Erlacher, Ayami Yoshimi, Charlotte M. Niemeyer, Martijn P. T. Ernst, Marc H. G. P. Raaijmakers, Nicolas Duployez, Andreas Flaum, Doris Steinemann, Brigitte Schlegelberger, Thomas Illig, Tim Ripperger

LEUKEMIA (2021)

Article Cell & Tissue Engineering

iPSC modeling of stage-specific leukemogenesis reveals BAALC as a key oncogene in severe congenital neutropenia

Benjamin Dannenmann, Maksim Klimiankou, Benedikt Oswald, Anna Solovyeva, Jehan Mardan, Masoud Nasri, Malte Ritter, Azadeh Zahabi, Patricia Arreba-Tutusaus, Perihan Mir, Frederic Stein, Siarhei Kandabarau, Nico Lachmann, Thomas Moritz, Tatsuya Morishima, Martina Konantz, Claudia Lengerke, Tim Ripperger, Doris Steinemann, Miriam Erlacher, Charlotte M. Niemeyer, Cornelia Zeidler, Karl Welte, Julia Skokowa

Summary: By editing CN patient-derived iPSCs using CRISPR-Cas9, this study established a model of stepwise leukemogenesis in CN/AML and identified the upregulation of BAALC and phosphorylation of MK2a as key events in leukemogenesis. Deleting BAALC or using a selective inhibitor of MK2a phosphorylation, CMPD1, can prevent cell proliferation and induce differentiation of CN/AML cells.

CELL STEM CELL (2021)

Article Oncology

Plasma Metabolome Signature Indicative of BRCA1 Germline Status Independent of Cancer Incidence

Judith Penkert, Andre Maertens, Martin Seifert, Bernd Auber, Katja Derlin, Ursula Hille-Betz, Philipp Hoermann, Norman Klopp, Jana Prokein, Lisa Schlicker, Frank Wacker, Hannah Wallaschek, Brigitte Schlegelberger, Karsten Hiller, Tim Ripperger, Thomas Illig

Summary: Individuals with pathogenic germline variant in breast cancer predisposition gene BRCA1 are predisposed to developing breast cancer. This study found systemic metabolic differences in individuals carrying the BRCA1 variant, independent of cancer incidence.

FRONTIERS IN ONCOLOGY (2021)

Article Oncology

Surveillance recommendations for DICER1 pathogenic variant carriers: a report from the SIOPE Host Genome Working Group and CanGene-CanVar Clinical Guideline Working Group

Jette J. Bakhuizen, Helen Hanson, Karin van der Tuin, Fiona Lalloo, Marc Tischkowitz, Karin Wadt, Marjolijn C. J. Jongmans

Summary: DICER1 syndrome is a rare genetic disorder that predisposes to a wide spectrum of tumors. Developing surveillance protocols for this syndrome is challenging due to uncertainty about clinical efficacy and varying appraisal of potential benefits and harms. Current recommendations include annual clinical examinations, chest X-rays, and ultrasounds, with additional procedures for consideration based on patient needs and potential efficacy. Further evaluation is necessary to expand the evidence base for DICER1 surveillance protocols.

FAMILIAL CANCER (2021)

Letter Hematology

The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy

Claire C. Homan, Sarah L. King-Smith, David M. Lawrence, Peer Arts, Jinghua Feng, James Andrews, Mark Armstrong, Thuong Ha, Julia Dobbins, Michael W. Drazer, Kai Yu, Csaba Bodor, Alan Cantor, Mario Cazzola, Erin Degelman, Courtney D. DiNardo, Nicolas Duployez, Remi Favier, Stefan Frohling, Jude Fitzgibbon, Jeffery M. Klco, Alwin Kramer, Mineo Kurokawa, Joanne Lee, Luca Malcovati, Neil V. Morgan, Georges Natsoulis, Carolyn Owen, Keyur P. Patel, Claude Preudhomme, Hana Raslova, Hugh Rienhoff, Tim Ripperger, Rachael Schulte, Kiran Tawana, Elvira Velloso, Benedict Yan, Paul Liu, Lucy A. Godley, Andreas W. Schreiber, Christopher N. Hahn, Hamish S. Scott, Anna L. Brown

HAEMATOLOGICA (2021)

Article Urology & Nephrology

Hereditary kidney cancer - easily clarified and diagnosed with ToSCaNA

Christian Fuhrmann, Christoph P. Czerner, Tim Ripperger, Florian Imkamp

Summary: The study conducted a literature search on five important hereditary syndromes with kidney cancer association and summarized the results. Based on the data, a diagnostic workflow and treatment path were established. The results showed that hereditary kidney cancer, although rare, could present in significant numbers in high-volume centers. For doctors who have limited experience with these types of tumors, the acronym and workflow provided in this study could be a valuable asset for clinical diagnosis.

AKTUELLE UROLOGIE (2022)

Article Hematology

Validation and clinical application of transactivation assays for RUNX1 variant classification

Melanie Decker, Anupriya Agarwal, Andreas Benneche, Jane Churpek, Nicolas Duployez, Adam Duvall, Martijn P. T. Ernst, Alisa Foerster, Hildegunn Hoberg-Vetti, Inga Hofmann, Michelle Nash, Marc H. G. P. Raaijmakers, Tor H. A. Tvedt, Adrianna Vlachos, Brigitte Schlegelberger, Thomas Illig, Tim Ripperger

Summary: In this study, the applicability of transactivation assays to investigate variants of the RUNX1 protein was evaluated. It was found that C-terminal RUNX1 variants require the development of new assays. Two variants of unknown significance were reclassified as likely pathogenic, and the (likely) pathogenic classification of two other variants was supported. The functionality of four variants of unknown significance was demonstrated, but reclassification to (likely) benign was challenging, indicating the need for reevaluating current classification guidelines. The clinical utility of the assays was illustrated in the context of seven families.

BLOOD ADVANCES (2022)

Review Oncology

Beyond Pathogenic RUNX1 Germline Variants: The Spectrum of Somatic Alterations in RUNX1-Familial Platelet Disorder with Predisposition to Hematologic Malignancies

Alisa Foerster, Melanie Decker, Brigitte Schlegelberger, Tim Ripperger

Summary: Pathogenic germline variants affecting RUNX1 are associated with platelet defects and hematologic malignancies. Somatic genetic alterations play a role in leukemic transformation, but the mechanism is not well understood. Through analyzing previously reported patients, we summarized the impact of RUNX1 variants on phenotype and somatic genetic alterations. Patients often harbor somatic variants in genes such as RUNX1, TET2, ASXL1, BCOR, PHF6, SRSF2, NRAS, and DNMT3A. These studies highlight the importance of somatic secondary events in the development of RUNX1-associated hematologic malignancies.

CANCERS (2022)

Article Oncology

Prevalence of pathogenic germline variants in women with non-familial unilateral tri-ple-negative breast cancer

Kerstin Rhiem, Silke Zachariae, Anke Waha, Sabine Grill, Anna Hester, Michael Golatta, Marion van Mackelenbergh, Tanja Fehm, Tanja Schlaiss, Tim Ripperger, Susanne Ledig, Cornelia Meisel, Dorothee Speiser, Kristina Veselinovic, Christopher Schroeder, Isabell Witzel, Julia Gallwas, Bernhard H. F. Weber, Christine Solbach, Bariyhe Aktas, Eric Hahnen, Christoph Engel, Rita Schmutzler

Summary: In this study, we investigated the prevalence of cancer predisposition genes in patients with TNBC and found that in patients diagnosed with TNBC before the age of 50 without a family history of breast or ovarian cancer, the prevalence of these genes reached 10.6%. Logistic regression analysis revealed that the younger the age at diagnosis, the higher the prevalence.

BREAST CARE (2023)

Letter Oncology

Reply to Li and Colleagues

Christian P. Kratz, Dmitrii Smirnov, Robert Autry, Natalie Jaeger, Sebastian M. Waszak, Anika Grosshennig, Riccardo Berutti, Mareike Wendorff, Pierre Hainaut, Stefan M. Pfister, Holger Prokisch, Tim Ripperger, David Malkin

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Article Oncology

Perception and management of cancer predisposition in pediatric cancer centers: A European-wide questionnaire-based survey

Jelena Lazic, Oskar A. Haas, Ugur Ozbek, Tim Ripperger, Anna Byrjalsen, Geertruij te Kronnie

Summary: The European Union-funded LEGEND project explored the perception and handling of genetic predisposition in childhood leukemia through a questionnaire-based survey. The results showed a high overall awareness and presence of identification and treatment for common predisposition syndromes. However, there is a high demand for continuous education and routinely updated resources.

PEDIATRIC BLOOD & CANCER (2023)

暂无数据